The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Abstract
Cancers of nearly all lineages harbor alterations that deregulate mitogen-activated protein kinase signaling, a crucial signaling pathway for tumor formation and maintenance. Of these, KRAS mutations are the most frequent gain-of-function alterations found in patients with cancer. In particular they represents the most common molecular alteration detected in non-small cell lung cancer (NSCLC) accounting for up to 25% of all oncogenic mutations. They were identified decades ago and prior efforts to target these proteins have been unsuccessful. KRAS mutation profiles (i.e. frequency of specific codon substitutions) in smokers and never-smokers are distinct and not all KRAS alterations are driver mutations. KRAS has evolved from a mutation with possible predictive value to a therapeutic target with great promise. Here, we will discuss the biology of KRAS in lung cancer and its clinical implications in oncology today and in the foreseeable future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“G12C and G12V mutations are shown to preferentially activate RAL signaling and G12D-mutant cell lines are shown to have high levels of phosphorylated AKT, suggesting preferential activation of PI3K-AKT-mTOR pathway [46, 47].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [47]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,318
Calcium's Role in Mechanotransduction during Muscle Development
Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Seger, R., & Krebs, E. G. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.9.7601337 · Cited by 3,631
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Research works printed but not linked: 1
- Renaud, 2018, KRAS-specific amino acid substitutions are associated with different responses to chemotherapy in advanced non–small-cell lung cancer, Clin Lung Cancer, 19, e919, 10.1016/j.cllc.2018.08.005 · DOI
Cited by
Sorted by citations
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 332
Self-citationRodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 246
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Self-citationOncogenic alterations in advanced NSCLC: a molecular super-highway
Friedlaender, A., Pérol, M., Banna, G. L., Parikh, K., & Addeo, A. (2024) · Biomarker Research · doi:10.1186/s40364-024-00566-0 · Cited by 150
Self-citationHuang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Current therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 121
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Addeo, A., Passaro, A., Malapelle, U., Banna, G. L., Subbiah, V., & Friedlaender, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102179 · Cited by 109
Self-citationTargeted Therapies in Early Stage NSCLC: Hype or Hope?
Friedlaender, A., Addeo, A., Russo, A., Gregorc, V., Cortinovis, D. L., & Rolfo, C. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176329 · Cited by 98
Self-citationKRAS G12C Mutations in NSCLC: From Target to Resistance
Addeo, A., Banna, G. L., & Friedlaender, A. (2021) · Cancers · doi:10.3390/cancers13112541 · Cited by 85
Self-citationKRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 80
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
Gao, G., Liao, W., Ma, Q., Zhang, B., Chen, Y., & Wang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.004 · Cited by 71
Finn, S. P., Addeo, A., Dafni, U. G., Thunnissen, E., Bubendorf, L., Madsen, L. B., Biernat, W., Verbeken, E. K., Hernández‐Losa, J., Marchetti, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.016 · Cited by 63
Self-citationFrisone, D., Friedlaender, A., Malapelle, U., Banna, G. L., & Addeo, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103008 · Cited by 65
Self-citationThe Landscape of Immunotherapy Resistance in NSCLC
Frisone, D., Friedlaender, A., Addeo, A., & Tsantoulis, P. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817548 · Cited by 60
Self-citationClinical potential of ATM inhibitors
Lavin, M. F., & Yeo, A. J. (2020) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2020.111695 · Cited by 51
The METeoric rise of MET in lung cancer
Friedlaender, A., Drilon, A. E. D. C., Banna, G. L., Peters, S., & Addeo, A. (2020) · Cancer · doi:10.1002/cncr.33159 · Cited by 51
Self-citationInvestigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
Alam, M., Hasan, G. M., Eldin, S. M., Adnan, M., Riaz, M. B., Islam, A., Khan, I., & Hassan, M. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114452 · Cited by 52
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Lindsay, C. R., Garassino, M. C., Nadal, E., Öhrling, K., Scheffler, M., & Mazières, J. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.005 · Cited by 46
Shi, J., Chen, Y., Peng, C., Kuang, L., Zhang, Z., Li, Y., & Huang, K. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.027545 · Cited by 45
Zhao, G., Ho, W., Chu, J., Xiong, X., Hu, B., Boakye‐Yiadom, K. O., Xu, X., & Zhang, X. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05007 · Cited by 43
Noordhof, A. L., Damhuis, R. A. M., Hendriks, L. E. L., Langen, A. J. D., Timens, W., Venmans, B. J. W., & van Geffen, W. H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.001 · Cited by 42
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Federico, A. D., Ricciotti, I., Favorito, V., Michelina, S. V., Scaparone, P., Metro, G., Giglio, A. D., Pecci, F., Lamberti, G., Ambrogio, C., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01436-y · Cited by 42
Kumar, P. A., Graziano, S. L., Danziger, N. A., Pavlick, D. C., Severson, E. A., Ramkissoon, S. H., Huang, R. S. P., Decker, B. J., & Ross, J. S. (2022) · Cancer Medicine · doi:10.1002/cam4.4971 · Cited by 38
Friedlaender, A., Metro, G., Signorelli, D., Gili, A., Economopoulou, P., Roila, F., Banna, G. L., Toma, A. D., Camerini, A., Christopoulou, A. N., et al. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1781249 · Cited by 39
Self-citationThouvenin, L., Olivier, T., Banna, G. L., Addeo, A., & Friedlaender, A. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986211004745 · Cited by 43
Self-citationFriedlaender, A., Kim, C., & Addeo, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00862 · Cited by 38
Self-citationKRAS Mutations in Squamous Cell Carcinomas of the Lung
Acker, F., Stratmann, J., Aspacher, L., Nguyen, T., Wagner, S., Serve, H. L., Wild, P. J., & Sebastian, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.788084 · Cited by 33
Thapa, R., Magar, A. T., Shrestha, J., Panth, N., Idrees, S., Sadaf, T., Bashyal, S., Elwakil, B. H., Sugandhi, V. V., Rojekar, S. V., et al. (2024) · MedComm · doi:10.1002/mco2.70018 · Cited by 33
Targeting KRAS in Non-Small Cell Lung Cancer
de la Fuente, E. C., Olmedo, M. E., Rueda, A. G., Lage, Y., & Garrido, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.792635 · Cited by 34
Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
Hasan, G. M., Hassan, M. I., Sohal, S. S., Shamsi, A., & Alam, M. (2023) · ACS Omega · doi:10.1021/acsomega.3c02424 · Cited by 29
Fu, N., Xi, R., Shi, X., Li, R., Zhang, Z., Li, L., Zhang, G., & Wang, F. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115988 · Cited by 29
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 27
Hou, X., Zhou, C., Liang, Z., Qiu, H., Zhou, Z. R., zheng, H., Li, Z., Wang, Y., Qi, X., Lu, L., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155093 · Cited by 26
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Jy, L., Bhandare, R. R., Boddu, S. H. S., SHAIK, A. B., Saktivel, L. P., Gupta, G., Negi, P., Barakat, M. M., Singh, S. K., Dua, K., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116275 · Cited by 25
Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides
Juliano, R. L. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa025 · Cited by 27
Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Kejík, Z., Kaplánek, R., Dytrych, P., Masařík, M., Veselá, K., Abramenko, N., Hoskovec, D., Vašáková, M., Králová, J., Pavel Martasek, E., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111879 · Cited by 23
The Role and Impact of Minimal Residual Disease in NSCLC
Frisone, D., Friedlaender, A., & Addeo, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01131-w · Cited by 21
Self-citationTargeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 23
Promising predictors of checkpoint inhibitor response in NSCLC
Friedlaender, A., & Alfredo, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1816173 · Cited by 20
Self-citationLi, K., Mao, S., Li, X., Zhao, H., Wang, J., Wang, C., Wu, L., Zhang, K., Yang, H., Jin, M., et al. (2023) · Cancer Science · doi:10.1111/cas.15721 · Cited by 20
Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer
Chevallier, M., Tsantoulis, P. K., Addeo, A., & Friedlaender, A. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20216 · Cited by 20
Self-citationThe discovery of novel imidazo[1,2- a ]pyridine derivatives as covalent anticancer agents
Song, Q., Zhang, Q., Fan, X., Kayaat, F., Lv, R., Li, J., & Wang, Y. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob00694a · Cited by 18
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 18
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
Krzyżanowska, N., Krawczyk, P. A., Wojas‐Krawczyk, K., Kucharczyk, T., & Milanowski, J. (2022) · Cells · doi:10.3390/cells11203280 · Cited by 16
Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer
Kirk, N. A., Kim, K., & Park, K.-S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00905-x · Cited by 17
Loss of Aryl Hydrocarbon Receptor Favors K-RasG12D-Driven Non-Small Cell Lung Cancer
Nacarino-Palma, A., Rejano-Gordillo, C. M., González-Rico, F. J., Ordiales-Talavero, A., Román, Á., Cuadrado, M., Bustelo, X. R., Merino, J. M., & Fernández‐Salguero, P. M. (2021) · Cancers · doi:10.3390/cancers13164071 · Cited by 16
Huang, L., Liao, Z., Liu, Z., Chen, Y., Huang, T., & Xiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900825 · Cited by 16
Rekowska, A. K., Rola, P., Wójcik-Superczyńska, M., Chmielewska, I., Krawczyk, P. A., & Milanowski, J. (2022) · Current Oncology · doi:10.3390/curroncol29050285 · Cited by 14
Guo, M. Z., Murray, J. C., Ghanem, P., Voong, K. R., Hales, R. K., Ettinger, D. S., Lam, V. K. L., Hann, C. L., Forde, P. M., Brahmer, J. R., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.08.002 · Cited by 12
Malik, P., Rani, R., Solanki, R., Patel, V. H., & Mukherjee, T. K. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00171 · Cited by 14
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 13
Spagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 15
Lee, S.-H., Jeon, Y., Kang, J. H., Jang, H., Lee, H., & Kim, S. (2020) · Cancers · doi:10.3390/cancers12061382 · Cited by 13
Urtecho, S. B., Provenzano, L., Spagnoletti, A., Bottiglieri, A., Pircher, C. C., Massa, G., Sposetti, C., Proto, C., Brambilla, M., Occhipinti, M. A., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108051 · Cited by 12
Du, Y., Lin, X., Feng, Q., Pan, X.-Y., Song, S.-L., & Yang, J.-L. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001180 · Cited by 10
Jin, M. Y., Lu, F., Li, X., Zhou, W., Li, S., Jiang, Y., Wu, H., & Wang, J. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24806 · Cited by 12
Li, Z., Ding, B., Xu, J., Mao, K., Zhang, P., & Xue, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580027 · Cited by 13
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Bersani, F., Morena, D., Picca, F., Morotti, A., Tabbò, F., Bironzo, P., Righi, L., & Taulli, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-189 · Cited by 10
Tang, Z., Zha, L., Liang, R., & Li, T. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01778-7 · Cited by 11
Kale, R. R., Samant, C., Nandakumar, K., Pai, K. S. R., & Bhonde, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151688 · Cited by 11
Boldig, C. M., Boldig, K., Mokhtari, S., & Etame, A. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136961 · Cited by 11
Lv, X., Li, Y., Wang, B., Wang, Y., Xu, Z., & Hou, D. (2024) · European Journal of Radiology Open · doi:10.1016/j.ejro.2024.100548 · Cited by 9
Sisoudiya, S. D., Tukachinsky, H., Keller-Evans, R. B., Schrock, A. B., Huang, R. S. P., Gjoerup, O. V., Pishvaian, M. J., Shroff, R. T., Sokol, E. S., Dennis, L. M., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00991-w · Cited by 9
Noordhof, A. L., Swart, E. M., Damhuis, R. A. M., Hendriks, L. E. L., Kunst, P. W. A., Aarts, M. J., & van Geffen, W. H. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100543 · Cited by 10
Dipeptidyl-peptidase 9 regulates the dynamics of tumorigenesis and metastasis in breast cancer
Heß, L., Aliar, K., Grünwald, B. T., Griffin, R., Lozan, A., Knöller, M., Khokha, R., Brummer, T., & Reinheckel, T. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167133 · Cited by 9
Mogenet, A., Barlési, F., Besse, B., Michiels, S., Karimi, M., Tran-Dien, A., Girard, N., Mazières, J., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.004 · Cited by 9
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 10
Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma
Fang, X., Liu, X., Weng, C., Wu, Y., Li, B., Mao, H., Guan, M., Lü, L., & Liu, G. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.47224 · Cited by 8
Radiogenomics in personalized management of lung cancer patients: Where are we?
Araujo-Filho, J., Mayoral, M., Horvat, N., Santini, F., Gibbs, P., & Ginsberg, M. (2022) · Clinical imaging · doi:10.1016/j.clinimag.2022.01.012 · Cited by 5
Diosmetin Affects Gene Expression on Human Lung Adenocarcinoma Cells
Song, C., Deng, S., Hu, H., Zheng, Z., Shen, B., Wu, X., Huang, M., Wang, J., & Wang, Z. (2022) · Journal of Oncology · doi:10.1155/2022/5482148 · Cited by 8
Lalić, N., Lovrenski, A., Ilic, M. P., Ivanov, O., Bojović, M., Lalić, I., Popević, S., Stjepanović, M., & Janjić, N. (2023) · Medicina · doi:10.3390/medicina59101723 · Cited by 8
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects
Fernandes, G., Rodrigues, A., Matos, C., Barata, F. J., Cirnes, L., Ferreira, L., Lopes, J. A., Felizardo, M., Fidalgo, P., Brito, U., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100725 · Cited by 7
Friedlaender, A., Liu, S. V., & Addeo, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000971 · Cited by 7
Self-citationCanadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Cheema, P. K., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Sacher, A. G., Sheffield, B. S., Snow, S. L., Vincent, M. D., et al. (2023) · Current Oncology · doi:10.3390/curroncol30070476 · Cited by 10
Abolfathi, H., Kordahi, M., Armero, V. E. S., Gagné, A., Desmeules, P., Orain, M., Fiset, P., Boudreau, D. K., Gaudreault, N., Lamaze, F. C., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108596 · Cited by 6
Molecular profiling of colorectal cancer in a genetically admixed Hispanic population
Montes‐Rodríguez, I. M., Centeno‐Girona, H., Rivera‐Lynch, C., Rivera, N., & Cruz-Correa, M. R. (2023) · Cancer Medicine · doi:10.1002/cam4.5888 · Cited by 6
Xia, Y., Zhang, S., Luo, H., Wang, Y., Jiang, Y., Jiang, J., & Yuan, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176157 · Cited by 6
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Toma, A. D., Russo, G. L., Signorelli, D., Pagani, F., Randon, G., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Ganzinelli, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103299 · Cited by 6
Recurrent central nervous system Rosai-Dorfman disease with KRAS mutation: a case report
Wang, Q., Ren, H., Liyuan, Z., Wang, J., & Zhong, D. (2023) · Diagnostic Pathology · doi:10.1186/s13000-022-01276-7 · Cited by 6
An Introduction to Cell Signalling Pathways and Their Dysregulation in Cancer
Talath, S., Wali, A. F., El‐Tanani, M., Al-Dhaheri, Y., Jain, P., & Mottershead, R. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_1 · Cited by 6
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6
Hussain, J., Chhabria, D., & Kirubakaran, S. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127290 · Cited by 5
Klein, M. A., Pragman, A. A., & Wendt, C. H. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.011 · Cited by 5
New driver alterations in non-small cell lung cancer: a narrative review
Filetti, M., Rossi, A., Salimbeni, B. T., Piras, M., Rogges, E., Napoli, A. D., Marchetti, P., & Giusti, R. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-19 · Cited by 4
He, Y., Guo, W.-F., Xu, M. Q., Huang, J., Zhang, X., Su, H., Hong, D., & Liu, Q. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221116834 · Cited by 4
Wu, J.-J., Lee, P.-H., Zheng, Z.-R., Huang, Y.-H., Tseng, J., Hsu, K.-H., Yang, T., Yu, S., Chen, K., & Chang, G. (2022) · Medicine · doi:10.1097/md.0000000000029381 · Cited by 4
Inci, T. G., Acar, S., & Turgut‐Balik, D. (2024) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2687 · Cited by 4
Gain-of-Function Variomics and Multi-omics Network Biology for Precision Medicine
Li, M. M., Awasthi, S., Ghosh, S. K., Bisht, D., Coban‐Akdemir, Z., Sheynkman, G., Sahni, N., & Yi, S. S. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3163-8_24 · Cited by 3
Future of lung cancer treatment
Petruzelka, L. B., Špaček, J., & Křížová, Ľ. (2021) · Klinicka onkologie · doi:10.48095/ccko2021s71 · Cited by 3
Chevallier, M., Chevallier-Lugon, C., Friedlaender, A., & Addeo, A. (2021) · Case Reports in Oncology · doi:10.1159/000513492 · Cited by 2
Self-citationBiomarkers for Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
Fuschillo, S., Battiloro, C., Rocco, D., Gravara, L. D., Motta, A., & Maniscalco, M. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0242 · Cited by 2
Kirsten Rat Sarcoma Mutation in South Indians with Non-Small Lung Cancer
Balaram, G., Thomas, R., Ghorpade, S. N., Kowsik, P. V., Dharman, B., Shivakumar, Y., Patil, S. G., Thungappa, S. C., Shashidhara, H. P., Bhattacharjee, S., et al. (2022) · Journal of Precision Oncology · doi:10.4103/jpo.jpo_7_22 · Cited by 2
Wu, S.-Y., Liao, E., Wen, Y., Wang, Y., Meng, H., Chou, H., & Chan, H. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111259 · Cited by 2
Davies, M. J. (2022) · Clinical journal of oncology nursing · doi:10.1188/22.cjon.245-251 · Cited by 2
Karim, N. A., Ullah, A., Pathrose, P., Fathallah, H., Perry, A. M., Morris, J. C., Wang, J., & Starnes, S. L. (2022) · Current Oncology · doi:10.3390/curroncol29070379 · Cited by 1
Targeting KRAS mutation in gastrointestinal cancers
Bicer, F., Akce, M., Piazza, G. A., Foote, J. B., & El‐Rayes, B. F. (2023) · F1000Research · doi:10.12688/f1000research.131688.1 · Cited by 1
KRAS G12C Inhibitors: New Drugs, A New Hope
Singhal, S., Schokrpur, S., Gandara, D. R., & Riess, J. W. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1383 · Cited by 1
Shrestha, A., Haque, M. A., Shrestha, P., Λάμπρου, Μ., Jois, S. D. S., Mikelis, C. M., & Mattheolabakis, G. (2025) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2025.1584801 · Cited by 1
Metadata
- Authors
- Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A.
- Affiliations
- University Hospital of Geneva (CH)
- Memorial Sloan Kettering Cancer Center (US)
- United Lincolnshire Hospitals NHS Trust (GB)
- Corresponding author
- Addeo, Alfredo
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 85
- Pages
- 101978
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W3004931546
- Cited by
- 118
- References
- 52
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 17 · 2023: 20 · 2022: 24 · 2021: 22 · 2020: 19
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Treatment Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS mutation, non-small cell lung cancer, druggable targets, MAPK signaling, gain-of-function mutations, smoking status, driver mutations, KRAS inhibitors, cancer therapeutics
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Forecasting, Humans, Immunotherapy, Lung Neoplasms, Male, Mutation, Gene Expression Regulation, Neoplastic, Survival Analysis, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
